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http://www.resource-allocation.com/content/12/1/12RESEARCH Open AccessA pilot study to assess feasibility of value based
pricing in Cyprus through pharmacoeconomic
modelling and assessment of its operational
framework: sorafenib for second line renal cell
cancer
Panagiotis Petrou* and Michael A TaliasAbstract
Background: The continuing increase of pharmaceutical expenditure calls for new approaches to pricing and
reimbursement of pharmaceuticals. Value based pricing of pharmaceuticals is emerging as a useful tool and possess
theoretical attributes to help health system cope with rising pharmaceutical expenditure.
Aim: To assess the feasibility of introducing a value-based pricing scheme of pharmaceuticals in Cyprus and explore
the integrative framework.
Methods: A probabilistic Markov chain Monte Carlo model was created to simulate progression of advanced renal
cell cancer for comparison of sorafenib to standard best supportive care. Literature review was performed and
efficacy data were transferred from a published landmark trial, while official pricelists and clinical guidelines from
Cyprus Ministry of Health were utilised for cost calculation. Based on proposed willingness to pay threshold the
maximum price of sorafenib for the indication of second line renal cell cancer was assessed.
Results: Sorafenib value based price was found to be significantly lower compared to its current reference price.
Conclusion: Feasibility of Value Based Pricing is documented and pharmacoeconomic modelling can lead to
robust results. Integration of value and affordability in the price are its main advantages which have to be weighed
against lack of documentation for several theoretical parameters that influence outcome. Smaller countries such as
Cyprus may experience adversities in establishing and sustaining essential structures for this scheme.
Classification codes: JEL 110, JEL 130, JEL 300
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 Value based pricing is a new innovative way of
pricing, which constitutes shifting from volume to
value.
 We developed a probabilistic Markov Model to
simulate disease progression of metastatic Renal Cell
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article, unless otherwise stated. We defined a price of sorafenib based on outcomes
compared to best supportive care.
 Value based price of sorafenib is significantly lower
compared to its current reference price.
 Many parameters have not been adequately
addressed.
 It demands a multidisciplinary team which may be
difficult for smaller countries to create and sustain.
Introduction
Health policy makers worldwide have to cope with steadily
increasing health care costs [1]. Pharmaceuticals constitutentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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a major concern for the sustainability of health systems.
In the oncology sector, situation is even more crucial.
In the USA, oncology medicines expenditure rose four
fold in seven years [2] while in Cyprus, we observed a
two fold increase of expenditure from 2005 to 2011 [3].
Most importantly, sales decomposition revealed that the
dominant prescribing pattern in the oncology category is
the shift from cheaper to more expensive new products.
Therefore new approaches to pricing and reimburse-
ment of drugs are a prerequisite in order to maximise in-
vestment and reduce unjustified costs. At the same time,
we must also safeguard the balance between static effi-
ciency (acceptable cost/ benefit ratio) and the dynamic ef-
ficiency (promoting Research & Development -R&D) [4],
since there are still unmet medical needs.
Currently, Cyprus applies external price referencing
(EPR), the dominant pricing policy within European Union.
For the scope of external price referencing, Drug Price
Control Committee uses one expensive, two medium and
one cheap EU countries. Simplicity of reference pricing
makes it an ideal approach for smaller countries. These ad-
vantages come at the cost of lack of any theoretical basis
and usually country selection is performed on secondary
factors, such as geographical proximity and access to
prices. In the WHO/HAI Project Medicine Prices and
Availability [5] it’s stated that it’s doubtful whether the
External Referencing Prices are “appropriate, efficient or
optimal in accordance with any objective criterion”. Fol-
lowing countries blindfold trail behind reference ones and
the risks of dissemination of flawed pricing approaches
(too high or too low prices) is eminent.
Moreover EPR has some other drawbacks which may
lead to price distortion:
 Many countries have implemented the clawback/
payback schemes as a mechanism to avoid budget
overshooting. Clawback / payback schemes [6]
provide the recovery of amounts granted in a
reimbursement system by payers given sales exceed
a defined threshold. Therefore, companies still retain
high price and avoid a price reduction which can
escalate to a rolling spillover effect on the other
reference countries. Clawback/ payback schemes
alleviate the impact of high prices locally, but these
schemes are not taken into consideration by the
countries that reference.
 Selection of right price is trivial since products may
carry many prices (retail, gross retail,
reimbursement, ex-factory, official wholesale).
 The referencing system reaches a steady state
following the convergence of prices and further
reductions are not anticipated.
 Reference pricing does not reward innovation. It’s path dependant which results to heavily
predictable outcomes.
In the context of aforementioned shortcomings of ref-
erence pricing, several health agencies have been experi-
menting with novel pricing approaches. Value based
pricing(VBP) has emerged in Europe and two of the
most important pharmaceutical market of Europe, UK
and Germany, are shifting into Value based pricing.Value based pricing
Value based pricing constitutes a paradigm shift from
volume to value. The aim is to convert the health bene-
fits that the product delivers, which exceed the health
benefits displaced in the broader health system and soci-
ety due to additional cost incurred [7], into monetary
value. The core of value based pricing is the incorpor-
ation of the product’s value into its price in the concept
of a holistic pathway. It also safeguards access to effect-
ive and innovative drugs by setting a price that reflects
the utility created [8]. From an industry perspective, this
constitutes a clear motive to pursue innovation, which
will be rewarded accordingly. From a payer’s perspective
this leads to optimality of available resources.
Taking all the above into consideration, we designed a
conceptual pilot study to assess practicability of adopting
value based pricing in Cyprus from a payer’s perspective.
We want to explore the feasibility of setting a price based
on value. We track down all issues, positive and negative,
stemming out of this process. Due to the fact that value
based pricing is a new approach, several methodological
and conceptual limitations exist. They include:
(a) The determination of affordability thresholds and
overall affordability.
(b) The relative lack of identifying, measuring and
valuing additional health benefits.
(c) Conversion from value to price.
(d) Data aggregation in heterogeneity population.
(e) Inherent challenges of measuring and comparing
utilities of different types, different diseases and
different stages of the same disease.
(f ) Time lapse between availability of clinical data and
best practice development.
(g) Ambiguity regarding optimal approaches of late
external benefits that cannot be captured in the
short term analysis [9].
Factors such as disease status and stage, bioethical argu-
ments, inclusion or not of societal costs, uncertainty of
results, robustness and reliability of clinical data infil-
trate value definition and currently there is an ongoing
debate regarding the actual definition [10].
Petrou and Talias Cost Effectiveness and Resource Allocation 2014, 12:12 Page 3 of 11
http://www.resource-allocation.com/content/12/1/12Methodology
We adopted the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) (Table 1) guidelines for
our economic evaluation [11].
Sorafenib, a Vascular Endothelial Growth Factor In-
hibitor (VEGF), was selected for the indication of second
line renal cell cancer (RCC) [12], since this therapeutic
category demonstrates significant sales increase which
exerts considerable pressures on pharmaceutical expend-
iture [3]. Due to the current financial recession and the
bailout agreement between Cyprus and Troika, there is a
need to assess all cost drivers, especially agents associated
with significant cost and clinical uncertainty. Moreover, in-
novative status of sorafenib implies that cost-containment
approaches such as tendering and internal price referen-
cing are relatively ineffective. As a comparative arm, we
have chosen best supportive care (BSC), according to
local guidelines in Cyprus. Although European Society
of Medical Oncology (ESMO) recommends axitinib and
pazopanib for second line treatment of renal cell carcin-
oma [13], current recession and austerity measures im-
pede introduction of new products in the formulary.
We define a probabilistic Markov analytical decision
Model which simulates disease progression [14,15] in RCC.
The Markov Model (Figure 1) is a memoryless process
which describes the evolution of disease between health
states in a stochastic way based on the transition probabil-
ities [16], which depend only on the current state of the
process and not on previous states. Three non- absorbing
health states were identified: Progression-free survival
(PFS), Progression disease (PD) and death. Patients are
supposed to enter the model in PFS state, after their diag-
nosis with metastatic RCC is confirmed (Figure 1). Due to
low life expectancy of these patients, we assume that each
cycle lasts one month and therefore the transition prob-
abilities are also defined per month [17]. Model was syn-
thesized in Winbugs 1.4.3 (Windows Bayesian Inference
Using Gibbs Sampling) [18], a software for specifying
complex Bayesian models [19]. Benefits of Bayesian
methodology have been extensively documented by
many authors [20-24].
We performed a literature review using mesh terms
“Sorafenib” “Carcinoma, Renal Cell” and “Randomised
Controlled trial” (Figure 2).
Literature review tracked down 36 studies eligible for
inclusion. We identified only one study that compares
sorafenib with BSC, which was also the unique study for
BSC [25]. TARGET trial is a large phase 3, high quality
and low bias study trial (Figure 2). This is a multicenter,
multinational, randomised double blind clinical trial and
it was also used for assessment of sorafenib by NICE
[12]. This study demonstrated the survival benefit of so-
rafenib over BSC [26], lasted for one and a half years
and recruited 903 patients with renal cell carcinoma thatwas resistant to standard therapy. Eighty three percent
of recruited patients received cytocine therapy as first
line. The median age of patients in this trial was 58 years.
Sorafenib was significantly superior compared to BSC for
both PFS and overall survival (OS): For PFS, the hazard ra-
tio (HR) was 0.51 (95% confidence interval [CI]: 0.43–0.60),
and for OS, the HR was 0.72 (95% CI: 0.54–0.94). Based
on the Progression free and Progression disease duration,
we estimated the transition probabilities which will be in-
corporated in the Markov model, according to the follow-
ing approach:
Risk of an event 1 monthð Þ
¼ 1− 0:5ð Þ^ 1=median time to eventð Þ
h
[27]
This can be easily derived through the equations:
P ¼ 1−e–Rand
R ¼ −ln 0:5½ = Time to event=number of treatment cyclesð Þ
[28]
Monthly transition probabilities to progressive disease
were defined as:
 0.104 for Sorafenib patients and,
 0.21 for BSC patients.
Monthly death probabilities (from progression free
state) were defined as:
 0.034 for Sorafenib patients and,
 0.042 for BSC patients.
Monthly death probabilities (from progressive state)
were defined as:
 0.05 for Sorafenib patients and,
 0.051 for BSC patients.
In order to incorporate uncertainty in the model, we
expressed these probabilities as beta distributions [29,30].
Beta distribution is defined as beta (α, β) and α denotes
number of patients that transit to next stage while β is the
total sample size minus number of patients who shift to
the next disease stage [31,32]. We set the time horizon as
a decade by the end of which all patients will shift into 3rd
stage. Due to absence of any official guidance regarding
technical parameters, we set discounting rate at 3.5% ac-
cording to current practice in UK [33] and Sweden [34].
Willingness to pay (WTP) threshold is not officially
Table 1 Cheers guidelines
Item Recommendation Input
1 Identify the study as an economic evaluation, or use more specific terms
such as “cost-effectiveness analysis” and describe the interventions
compared.
Value based pricing of Sorafenib compared to best supportive care.
2 Provide a structured summary of objectives, perspective, setting,
methods (including study design and inputs), results (including
base-case and uncertainty analyses), and conclusions.
Objectives, perspective, setting, methods (including study design and
inputs), results including base-case and uncertainty analyses), and
conclusions are included in the manuscript.
3 Provide an explicit statement of the broader context for the study.
Present the study question and its relevance for health policy or practice
decisions.
Definition of value based price for sorafenib. Definition of a price that
reflects added value and utility of sorafenib treatment.
4 Describe characteristics of the base-case population and subgroups ana-
lyzed including why they were chosen.
Patients presented with metastatic RCC (as per indication)
5 State relevant aspects of the system (s) in which the decision (s)
need (s) to be made.
Cyprus Public Health Care Sector
6 Describe the perspective of the study and relate this to the costs being
evaluated.
Costs from Payer’s perspective in Cyprus
7 Describe the interventions or strategies being compared and state why
they were chosen.
BSC vs sorafenib, a new VEGR agent product for this indication Bsc was
chosed based on current local practice. Sorafenib was chosen since it
belongs in the group of medicines with significant budget impact and high
annual sales increase.
8 State the time horizon (s) over which costs and consequences are being
evaluated and say why appropriate.
Time horizon is 10 years, by the end of this period all patients will transit
into 3 stage (death).
9 Report the choice of discount rate (s) used for costs and outcomes and
say why appropriate.
3.5% as per literature
10 Describe what outcomes were used as the measure (s) of benefit in the
evaluation and their relevance for the type of analysis performed.
QALY due to its universal acceptance
11 Single study–based estimates: Describe fully the design features of the
single effectiveness study and why the single study was a sufficient
source of clinical effectiveness data.
A high quality low bias clinical trial [13]. In the Methodology section
12 Synthesis-based estimates: Describe fully the methods used for the
identification of included studies and synthesis of clinical effectiveness data.
N/A
13 Model-based economic evaluation: Describe approaches and data
sources used to estimate resource use associated with model health
states. Describe primary or secondary research methods for valuing each
resource item in terms of its unit cost. Describe any adjustments made
to approximate to opportunity costs.
In the Methodology section
14 Report the dates of the estimated resource quantities and unit costs.
Describe methods for adjusting estimated unit costs to the year of
reported costs if necessary. Describe methods for converting costs into a
common currency base and the exchange rate.
In the Methodology section
15 Describe and give reasons for the specific type of decision-analytical model
used. Providing a figure to show model structure is strongly recommended.
In the Methodology section. Figure 1
16 Describe all structural or other assumptions underpinning the decision-
analytical model.
In the Methodology section
17 Describe all analytical methods supporting the evaluation. In the Methodology Section
18 Report the values, ranges, references, and, if used, probability
distributions for all parameters. Report reasons or sources for
distributions used to represent uncertainty where appropriate. Providing
a table to show the input values is strongly recommended.
Tables 2, 3 and 4
19 For each intervention, report mean values for the main categories of
estimated costs and outcomes of interest, as well as mean differences
between the comparator groups. If applicable, report incremental cost-
effectiveness ratios.
In Results section. Table 5
20 Model-based economic evaluation: Describe the effects on the results of
uncertainty for all input parameters, and uncertainty related to the
structure of the model and assumptions.
Sensitivity analysis was performed. Table 6
21 Summarise key study findings and describe how they support the
conclusions reached. Discuss limitations and the generalisability of the
findings and how the findings fit with current knowledge
In Results section
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Figure 1 Markov model for second line m RCC.
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tions of WHO [35] regarding utilisation of multiplies of
Gross Domestic Product (GDP) per capita as a proxy for
WTP threshold. In 2012 the estimated GDP per capita
current prices was 20,517 euro [36], therefore we define
the WTP threshold at 60,000 euro. Since sorafenib is an
orphan drug, we used the highest recommended level. We
performed one way sensitivity analysis in order to identify
which variables and to which extent affect outcome.
Cost distribution of general medical and other pharma-
ceutical costs (Table 2) (excluding sorafenib cost) was as-
sumed to follow gamma distribution since typically costs
are non- normally distributed, highly skewed and demon-
strate kurtosis [37]. Method of moments [38] was applied
in order to estimate parameters of this distribution.
Sorafenib costs were denoted by a uniform distribution
as per the recommended (approved) daily dosage since
we assume that all patients receive recommended daily
dose. We adopted the health state utilities as reported by
Thomson [12] which were assessed through the use of
UK EQ-5D: health state utilities of 0.76 (s.e. 0.03) for
PFS and 0.68 (s.e. 0.04) for PD. Since utility value aredefined between 0 and 1, we assume that they follow a
beta distribution as following [39,40]:
 Progression Free State (153.26, 48.4),
 Progressive disease state (91.8,43.2).
Markov Model was loaded with an initial cohort of
1,000 patients. Patients were supposed to be on the sec-
ond line of treatment with sorafenib with an indication of
metastasis. We discarded the first 50,000 iterations of
simulation to ensure stability of the model and we per-
formed another 50,000 iterations to ensure convergence
and accuracy of data. We checked convergence through
trace plots of samples and standard error of the results.
Other medical and pharmaceutical costs
Cancer patients in Cyprus, with annual income less than
150,000 euro are entitled to free public medical care.
Utilization of pharmaceutical and medical cost was assessed
based on National guidelines and availability of products
listed in the national formulary. Costs of pharmaceuticals
(sorafenib and adjuvant pharmaceutical care) were extracted
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Figure 2 Flow Diagram of literature review of Sorafenib in Second line renal cell carcinoma.
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culated based on 2012 database [41,42] (Tables 3 and 4).
Results
Treatment with sorafenib results to incremental gain 0,1605
QALY per patient, compared to BSC. This would lead to
16996 euro cost per sorafenib patient (CI 95%: 13140-
18950) compared to 7336 euro per patient on best support-
ive care (CI 95%: 6327.0- 8468.0). Our Value based pricing
approach indicates that under a 60,000 theoretical WTP
threshold, price of sorafenib should be set at 1816 euro per
package, a price notably lower compared to current price.
Under current price (2880 per package) the Incremental
Cost Effectiveness Ratio (ICER) is 102,879 and the health




















(1336, 4.8) (3696, 4.8) (28
1Provides that patients will continue sorafenib for one month after progression untSensitivity analysis
We performed one way sensitivity analysis. ICER was
proved to be significant sensitive to the price of sorafenib,
while medical and other pharmaceutical had a minimum
impact on ICER. ICER is also sensitive to utilities and to
PFS while it’s less sensitive to OS (Table 6).
Discussion
Health care costs are rapidly expanding. Several cost
containment approaches such as price reductions, in-
ternal price referencing, tendering and risk-sharing
have been applied extensively. Although undisputedly
potent in the short-term, tendering and price reduction







1st and 2nd month
3nd Month
and further on
2880 357 1499 1 770
niform Gamma Gamma Gamma
80,2900) (1714, 4.8) (7196, 4.8) (3696, 4.8)
il diagnosis is confirmed.
Table 3 Health services use and costs
Parameter PFS PD
Consultation CT scan Consultation
Sorafenib 1 specialist visit €40 €256 (every 3 months) 1 GP 2 nurses 1 psychologist €70
Annual costs related to hypertension: 3 visits € 60
BSC 1 GP 2 nurses 1 psychologist €70 €256 (every 6 months) 1 GP 2 nurses 1 psychologist €70
Hospitalization (Daily) €135 €135
Blood test s (Full blood count, liver
function SGPT SGOT and creatinine
€157 €157
Monthly Costs (unless otherwise specified).
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categories. On the other hand, risk sharing schemes
were implemented to tackle uncertainty primarily for
short term and due to their binary evaluation context
they tend to benefit insurer and sustainability is severely
doubted [43]. Therefore they cannot be considered as a
long term approach. Other current pricing schemes
such as EPR do not promote innovation, while some au-
thors argue that EPR leads to high prices of medicines
which are not aligned to their value [44].
Value based pricing is a paradigm shift that distributes
risk among payer and industry and offers measurable
value to payers. Our approach indicates that value based
pricing is a feasible approach in Cyprus Health sector.
Nevertheless, several practical issues were raised during
the procedure that have to be tackled before value based
pricing is disseminated. We identified only one clinical
study, whose design matches current practice in Cyprus,
nevertheless this would not be the norm for the majority
of drugs. Marketing authorization holders run rando-
mised controlled trials for regulatory purposes, whose
design deviates from real life settings due to comparator
choice, exclusion and inclusion criteria, patient popula-
tion, duration of the trials, setting, outcome measures
and duration. Assessing data and synthesizing relevant
models for economic evaluation raise substantially com-
plexity factor and this constitutes value based pricing a
lengthy, labor and expertise demanding process. It would
demand strong support and commitment by government
and mainly a multidisciplinary pool of people with the
appropriate health economic, statistical and epidemio-
logical skills. A small country such as Cyprus may strug-
gle to maintain the necessary human resources required
especially given current financial recession. Another obs-
tacle emerging from size of Cyprus deals with maximum
output capacity. A proper economic evaluation may span
up to one year, and it’s doubtful whether current Health
context can support more than one committee. Therefore,
relevant output capacity of this committee will be low and
full market coverage is illusive. Consequently it’s expected
that given that such a committee is assembled, it can focus
only on selected products, with significant disease orbudget impact. This could create inequalities among
pharmaceutical market and create 2 tier products.
Cyprus, due to its small size and remote location, is
classified as a non-attractive small pharmaceutical mar-
ket [45]. A distinct characteristic of this market is the
existence of low competitive forces, which tend to shift
monopoly power to supplier. Supplier’s monopoly power
is also augmented by entry barriers, such as obligations
of marketing authorization holder to supply summary of
product’s characteristics in Greek, along with Greek la-
beled packages. Being a small market deters the devel-
opment of alternative supply chains, such as parallel
imports, which could have compromised dominant pos-
ition of a single supplier. Therefore, we would need to
assess potential exit of pharmaceutical industries from
Cyprus, in case of price reductions. However, this has to
be weighed against a much faster introduction of prod-
ucts to the formulary.
Sorafenib has two indications, renal and liver cancer.
Under proposed value based pricing, this will create se-
vere implications since potentially sorafenib will carry 2
prices, which will further increase complexity factor of re-
imbursement process. This may lead to a weighted value
based pricing, based on estimated utilization data.
Establishment of a WTP threshold remains uncharted
territory for many countries primarily due to ethical rea-
sons and the decision making is performed on the basis
of unpublished pertinent thresholds. Cost effectiveness
has a comparative and a limiting context since all medi-
cines would be cost effective under an infinitely large
WTP threshold. For our study we adopted recommenda-
tions of WHO, which provides that multiplies of per
capita domestic product can be used as economic thresh-
old. More importantly, this approach takes into consider-
ation financial capacity of each country. According to this
approach, three time per capita domestic product is the
highest WTP threshold; anything above this is considered
to be non- cost effective and resources could create more
health utility diverted to other therapeutic territories. This
is in line with differential price concept and in contrast to
external price reference, this allows affordability of each
country to contribute to prices of pharmaceuticals.
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Table 5 Threshold leves and Corresponding value based price of Sorafenib
Willingness to pay Threshold 20,000 40,000 60,000 >100,00 (102,616)







(CI 95% 20,000 -28220)
Cost of bsc arm 7336.0
(CI 95%: 6327.0- 8468.0).
7336.0
(CI 95%: 6327.0- 8468.0).
7336.0
(CI 95%: 6327.0- 8468.0).
7336.0
(CI 95%: 6327.0- 8468.0).
Incremental QALY gains 0,1605 QALY 0,1605 QALY 0,1605 QALY 0,1605 QALY
Incremental cost 3284 6424 9630 16470
VBP of sorafenib 810 1325 1816 2880
Petrou and Talias Cost Effectiveness and Resource Allocation 2014, 12:12 Page 9 of 11
http://www.resource-allocation.com/content/12/1/12Some authors take a step forward and suggest the
introduction of varying thresholds level: each one ad-
dressing a specific health state under the condition that
ethical and legal concerns can be addressed. A higher
WTP threshold would probably suit better condition
with greater burden of illness, such as rare and orphan
diseases, end of life treatment, highly innovative prod-
ucts and medicines that exhibit wider societal benefits,
such as benefits to carers [46]. Many authors argued
about potential extra weight of QALY in end of life
treatments [47] while others debate that even a QALY at
the end of life actually varies according [48] to the way it
was obtained, with gain in palliative care being superior
[49,50] to gains in life expectancy. Since all health pro-
grams actually compete for funds it’s possible that this
diversity may be beneficial for some patients and injuri-
ous for others. Ginette Camps-Walsh [7] suggests 5 dif-
ferent categories of threshold within NHS which
differentiate acute, chronic, paediatric, rare and end of
life diseases. The categories above have varying degrees
of treatment options and as a result, each category has
diverse unmet medical needs.Table 6 Sensitivity analysis
Parameter Baseline value S
Sorafenib price 1816 (per month)




QALY 0.76 – 0.68
QALY 0.76 – 0.68
Medical and other pharmaceutical costs
Medical and other pharmaceutical costs
Increase of PFS and OS 10%
Increase of OS 10%
Increase of PFS 10%
Decrease of PFS and OS 10%
Decrease of OS 10%
Decrease of PFS 10%Capitalising on this, we adopted the higher WTP
threshold, due to orphan drug status of sorafenib.
The above issue is also linked to utilisation of different
health state measure tools. It’s accepted that available
health state measurement tools [51] can deliver varying
results and it’s also documented that patients in different
stages of the same disease have different perception of
time [52] and health state preferences [53].
These findings create further complications regarding
the selection of endpoints of the study (Overall survival
or Progression free survival) which must be consistent in
order to ensure homogeneity among potentially com-
parative products.
Comparator selection and specifically the base care
product, is of paramount importance. In a time series
setting, the price of future products will be a step-up de-
pendant based on past and current value based prices.
In our case, we compared sorafenib to BSC, with BSC
being the base case product. Upon future introduction
of axitinib, its price will greatly depend on price of soraf-
enib and there will be notable differences between soraf-
enib’ s reference (2880 euro) and sorafenib’ s value basedensitivity analysis New price ICER Base case
50% reduction 908 24,190 60,000
5 YEARS 1860 60,266 60,000
0 2455 45,279 60,000
1.5 2124 51,025 60,000
5 1695 67,203 60,000
0,836 0.748 2013 54,738 60,000
0.684- 0.612 1711 66,863 60,000
Increase 20% 1926 57,407 60,000







Petrou and Talias Cost Effectiveness and Resource Allocation 2014, 12:12 Page 10 of 11
http://www.resource-allocation.com/content/12/1/12price (1816 euro).The level of complexity will further
rise given that in oncology regimens, it’s not rare to en-
counter expensive products, apart from primary ones,
which are given as adjuvant or to cure side effects. It’s still
unknown how to address this issue regarding products
that were priced ex post and products that will be priced
ex ante.
Another decisive task is to express all values into money:
Some authors suggest the net-benefit while other authors
argue for the use of multicriteria decision analysis, by using
weight value for each benefit type [54].
Value based pricing is expected to engage R & D com-
panies in a quest for really innovative products, but it
may deter companies from investing into territories, in
which marginal benefits are anticipated [55]. Another
pending issue is the pricing of equivalent products and
the concern that this will impede further price competi-
tions which have led to massive reductions in some thera-
peutic categories, such as statins [56].
As proved by our analysis value based pricing does not
result in high pharmaceutical prices when society’s WTP
is known and under a specific context it can be considered
a cost containment tool [57]. This does not come under
surprise since oncology products due to their innovative
mode of action status, high R & D costs and considerable
failure rates ask for higher prices.
In our study we transferred health utilities from pub-
lished study. Value based pricing framework in other
countries, such as Germany provides that a product gets a
provisional price, and afterwards “real life effectiveness
data” [58] are gathered, which will be utilized to set a
value based price [59]. For new products this preferably
has to be carried out in national level. This is in line with
other approaches which provide that new products get a
price based on an ex ante evaluation while existing prod-
ucts get a price based on a rolling ex post evaluation [60].
Conclusions
A value based pricing scheme is feasible in Cyprus. Esti-
mated value based price of sorafenib is significantly lower,
which is in line with findings of other authors [61].
Although many issues are still pending, incorporation
of value and affordability into the product price, comprise
essential rationale for its further dissemination. Industry
and health authorities must engage in a dialogue to crystallize
all aspects since despite its potentials, value based pricing
displays a high complexity factor.
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